Evofem Bioscienc Stock Price, News & Analysis

Evofem Biosciences plans to offer and sell $30 million of its common stock in an underwritten public offering, with a potential additional $4.5 million from underwriters. The offering is contingent on market conditions and does not guarantee completion or specific terms. Proceeds will support commercialization of Phexxi contraceptive gel in the U.S., fund the ongoing EVOGUARD Phase 3 clinical trial for EVO100, and cover general corporate expenses. The offering is registered under Form S-3 and details will be filed with the SEC.

Evofem Biosciences (NASDAQ: EVFM) announced impressive initial results from its "Get Phexxi" direct-to-consumer campaign, launched on Valentine's Day. The campaign, aimed at promoting its non-hormonal birth control, Phexxi, generated over 173 million views in three weeks. Key metrics included a 73% rise in monthly ex-factory sales of Phexxi in February and a significant boost in brand awareness, with total prescriptions for Phexxi growing by 32%. The number of healthcare providers prescribing Phexxi increased by 25% in February 2021 compared to January.

Evofem Biosciences (NASDAQ: EVFM) announces the publication of the AMPREVENCE trial manuscript in the American Journal of Obstetrics and Gynecology. The trial of EVO100, a preventive gel for chlamydia and gonorrhea, met primary and secondary efficacy endpoints, showing a 50% reduction in chlamydia and 78% in gonorrhea infections in women at high risk. Currently, there are no FDA-approved products for these infections. Evofem is enrolling patients for the EVOGUARD Phase 3 trial, with data expected in mid-2022, aiming for FDA submission by the end of 2022.

Evofem Biosciences (NASDAQ: EVFM) reported its 2020 financial results, highlighting its U.S. launch of Phexxi, a non-hormonal birth control method. The 'Get Phexxi' campaign generated over 115 million views, resulting in a 362% increase in direct searches. Despite this, net product sales for Q4 were approximately $170,000, with a net loss of $40.6 million. For the year, net sales totaled around $450,000, with a net loss of $142.3 million. Evofem secured a $25 million strategic investment to fund clinical trials and boost market access. The company continues to focus on addressing unmet medical needs for women.

Evofem Biosciences (NASDAQ: EVFM) announced its presentation at the H.C. Wainwright Global Life Sciences Conference on February 23, 2021. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, a non-hormonal birth control method. The presentation will be available for on-demand listening starting March 9, 2021, at 7:00 a.m. ET on their website. Additionally, on Valentine's Day, Evofem launched a DTC campaign called 'Get Phexxi' to enhance awareness of its product.

Phexxi® is the first and only hormone-free prescription vaginal gel in the U.S. for pregnancy prevention.

Evofem Biosciences, Inc. (NASDAQ: EVFM) is set to hold a webcast and conference call on March 4, 2021, at 4:30 p.m. ET, to discuss its financial results and business highlights for the fourth quarter and full year ended December 31, 2020. Investors can access the live webcast through the Company’s website or by dialing (866) 503-5561 for U.S. callers. The conference ID is 9928997. Evofem focuses on innovative women’s health solutions, including the hormone-free contraceptive Phexxi®. More details can be found at the company’s website.

Evofem Biosciences, Inc. (NASDAQ: EVFM) has launched its "Get Phexxi" direct-to-consumer campaign to raise awareness about Phexxi®, a non-hormonal birth control method approved by the FDA in May 2020. The campaign addresses the 21 million women in the U.S. at risk for pregnancy who are not using hormonal contraception. The initiative, launched on Valentine's Day, aims to educate women on Phexxi's benefits as an on-demand contraceptive. The campaign includes a national TV commercial and a targeted digital marketing strategy, responding to frustrations expressed by women regarding existing birth control methods.

Evofem Biosciences (NASDAQ: EVFM) and NCODA have partnered to enhance awareness of Phexxi®, a non-hormonal contraceptive, among female cancer patients. This collaboration, initiated on World Cancer Day, aims to provide resources and educational materials for oncology teams to support patients in selecting the best contraceptive options. With over 800,000 new cancer cases reported annually in women in the U.S., the need for non-hormonal options like Phexxi, approved in May 2020, is critical as many cancer treatments necessitate birth control use.